Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

New phase II trial explores ramucirumab for advanced, pretreated biliary cancers

Jan. 4, 2016

Rovalpituzumab tesirine from Stemcentrx receives FDA orphan drug designation

Dec. 30, 2015

Valor initiates first-in-human study of IGN-002 for NHL

Dec. 30, 2015

Sacituzumab govitecan has antitumor activity in patients with triple-negative breast cancer

Dec. 29, 2015

Genmab confirms agreement to transfer remaining ofatumumab rights

Dec. 22, 2015

CHMP recommends approval of Lilly's necitumumab and ramucirumab

Dec. 22, 2015

Saronic files IND for phase I/II trial of SBI-1997 for hepatocellular carcinoma

Dec. 22, 2015

FDA approves Keytruda for first-line treatment of unresectable or metastatic melanoma

Dec. 21, 2015

Cells transduced with the inducible caspase-9 suicide gene well tolerated in children

Dec. 21, 2015

First clinical trial results for nivolumab in ovarian cancer

Dec. 21, 2015

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...